Destiny Pharma’s XF-73 could be the first drug approved for the US FDA’s newly defined indication of prevention of post-surgical staphylococcal infection
UK-based developer of anti-microbial drugs, Destiny Pharma, has welcomed the news from the US FDA for acceptance of an Investigational…